HUTCHMED Announces That Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HUTCHMED Announces That Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals ("Inmagene") has exercised options to license two drug candidates discovered by HUTCHMED, IMG-007 and IMG-004 (the "Options") pursuant to the terms of the strategic partnership announced on January 11, 2021. Following the exercise of the Options and subject to receipt by HUTCHMED of ordinary shares representing approximately 7.5% of shares (fully diluted) in Inmagene, Inmagene will be granted an exclusive license to further develop, manufacture and commercialize these two drug candidates worldwide.
和黃醫藥（中國）有限公司（“和黃醫藥”）（納斯達克/AIM：HCM；香港交易所：13）今天宣佈，英邁基生物製藥（“Inmagene”）已根據2021年1月11日宣佈的戰略合作伙伴關係條款，行使期權，對和黃醫藥發現的兩種候選藥物 IMG-007 和 IMG-004（“期權”）進行許可。行使期權後，在和黃醫藥收到佔Inmagene約7.5％股份（完全攤薄）的普通股的前提下，Inmagene將獲得在全球範圍內進一步開發、製造和商業化這兩種候選藥物的獨家許可。
